Company: NDRA
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001654954-25-005770
Chunk: 4

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
 liability  (408,562)  - Changes in operating assets and liabilities:        Decrease in prepaid expenses  88,854   42,609 Increase in inventory  -   (231,791)Decrease in accounts payable and accrued liabilities  (68,604)  337,711 Decrease in lease liability  2,884   (41,855)Net cash used in operating activities  (1,293,129)  (2,144,312)         Cash Flows from Investing Activities        Purchases of fixed assets  (17,280)  (27,000)Proceeds from sale of fixed assets  -   3,204 Net cash used in investing activities  (17,280)  (23,796)         Cash Flows from Financing Activities        Proceeds from issuance of common stock  145,803   419,967 Proceeds from warrant issuances and exercises  -   77,419 Repayment of loan  -   (28,484)Net cash provided by financing activities  145,803   468,902          Net decrease in cash  (1,164,606)  (1,699,206)         Cash, beginning of period  3,229,480   2,833,907          Cash, end of period $2,064,874  $1,134,701          Supplemental disclosures of cash items        Interest paid $14,855  $8,801 Income tax paid $-  $-          Supplemental disclosures of non-cash items        Stock dividend payable $-  $(4,932)Right of use asset $546,216  $313,715 Lease liability $587,303  $324,064 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 6Table of Contents

ENDRA Life Sciences Inc.

Notes to Condensed Consolidated Financial Statements

For the three months ended March 31, 2025 and 2024

(Unaudited)

Note 1 - Nature of the Business ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) has developed and is continuing to develop technology for characterizing tissue non